Inside Kyron.bio’s Bold Bet to Rewrite the Rules of Antibody Drug Design

For all the buzz around antibody therapies, one overlooked culprit keeps holding them back: sugars. Paris-based Kyron.bio is tackling the hidden complexity of glycosylation — the way sugars attach to therapeutic proteins — with a platform that promises safer, longer-lasting drugs.